Compare Stocks: STTK, BEAM, IRON, and IMNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.50 +0.5%	$26.67	$20.23 ▼ $38.26	$2.52B	2.2	1.96 million shs	1.50 million shs
IMNM Immunome	$20.90 +0.0%	$25.35	$11.55 ▼ $30.06	$2.37B	2.55	1.29 million shs	1.17 million shs
IRON Disc Medicine	$64.51 +1.4%	$74.99	$40.00 ▼ $99.50	$243.92M	0.93	545,956 shs	684,729 shs
STTK Shattuck Labs	$6.73 -1.6%	$6.91	$1.70 ▼ $8.33	$675.44M	1.09	1.44 million shs	1.84 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.45%	+0.95%	-16.35%	-29.58%	+1.53%
IMNM Immunome	+0.05%	-2.38%	-23.53%	-11.48%	+84.30%
IRON Disc Medicine	+1.41%	-1.12%	-19.41%	-15.41%	-3.77%
STTK Shattuck Labs	-1.61%	+10.87%	-2.60%	-4.54%	+182.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.50 +0.5%	$26.67	$20.23 ▼ $38.26	$2.52B	2.2	1.96 million shs	1.50 million shs
IMNM Immunome	$20.90 +0.0%	$25.35	$11.55 ▼ $30.06	$2.37B	2.55	1.29 million shs	1.17 million shs
IRON Disc Medicine	$64.51 +1.4%	$74.99	$40.00 ▼ $99.50	$243.92M	0.93	545,956 shs	684,729 shs
STTK Shattuck Labs	$6.73 -1.6%	$6.91	$1.70 ▼ $8.33	$675.44M	1.09	1.44 million shs	1.84 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.45%	+0.95%	-16.35%	-29.58%	+1.53%
IMNM Immunome	+0.05%	-2.38%	-23.53%	-11.48%	+84.30%
IRON Disc Medicine	+1.41%	-1.12%	-19.41%	-15.41%	-3.77%
STTK Shattuck Labs	-1.61%	+10.87%	-2.60%	-4.54%	+182.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	100.00% Upside
IMNM Immunome	2.79	Moderate Buy	$34.25	63.88% Upside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	70.80% Upside
STTK Shattuck Labs	3.00	Buy	$13.33	98.12% Upside

Current Analyst Ratings Breakdown

Latest STTK, BEAM, IRON, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	STTK Shattuck Labs	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$11.00 ➝ $14.00
10/2/2026	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $19.00
9/30/2026	IMNM Immunome	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$24.00
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/21/2026	IMNM Immunome	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	IRON Disc Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$128.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	16.22	N/A	N/A	$12.20 per share	2.01
IMNM Immunome	N/A	N/A	N/A	N/A	$5.75 per share	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
STTK Shattuck Labs	$1M	675.44	N/A	N/A	$1.30 per share	5.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest STTK, BEAM, IRON, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.67%	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
IMNM Immunome	N/A	15.08	15.08
IRON Disc Medicine	0.09	24.14	24.14
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
IMNM Immunome	44.58%
IRON Disc Medicine	83.70%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
IMNM Immunome	7.21%
IRON Disc Medicine	3.76%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
IRON Disc Medicine	165	3.83 million	3.69 million	Not Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable

STTK, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

Shattuck Labs (NASDAQ:STTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

October 2 at 8:05 AM | marketbeat.com

Financial Contrast: MDxHealth (NASDAQ:MDXH) and Shattuck Labs (NASDAQ:STTK)

October 2 at 6:15 AM | americanbankingnews.com

Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug

October 1 at 12:02 PM | finance.yahoo.com

Shattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa Trial

October 1 at 12:02 PM | rttnews.com

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

October 1 at 7:00 AM | globenewswire.com

Shattuck Labs (NASDAQ:STTK) Shares Up 11.9% - Time to Buy?

September 30 at 11:39 AM | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Stock Rated "Buy" by Sell-Side Brokerages

September 30 at 2:44 AM | americanbankingnews.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Buy" from Brokerages

September 25, 2026 | marketbeat.com

Shattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Bank of New York Mellon Corp Buys New Stake in Shattuck Labs, Inc. $STTK

September 10, 2026 | marketbeat.com

Bank of America Corp DE Cuts Holdings in Shattuck Labs, Inc. $STTK

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Makes New Investment in Shattuck Labs, Inc. $STTK

September 8, 2026 | marketbeat.com

3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.

September 7, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.58 Million in Shattuck Labs, Inc. $STTK

September 4, 2026 | marketbeat.com

BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK

September 3, 2026 | marketbeat.com

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STTK, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.50 +0.11 (+0.45%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$24.53 +0.03 (+0.11%)

As of 10/2/2026 07:57 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Immunome NASDAQ:IMNM

$20.90 +0.01 (+0.05%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$20.90 0.00 (-0.02%)

As of 10/2/2026 07:30 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Disc Medicine NASDAQ:IRON

$64.51 +0.90 (+1.41%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$64.95 +0.44 (+0.68%)

As of 10/2/2026 07:30 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Shattuck Labs NASDAQ:STTK

$6.73 -0.11 (-1.61%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.63 -0.10 (-1.44%)

As of 10/2/2026 07:56 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, BEAM, IRON, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, BEAM, IRON, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STTK, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, BEAM, IRON, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, BEAM, IRON, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STTK, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools